Overview

• Eli Lilly will invest $27 billion to construct four new pharmaceutical manufacturing plants in the U.S., focusing on active pharmaceutical ingredients and injectable medicines.
• The new facilities are expected to create over 3,000 high-skilled jobs and 10,000 construction jobs, with locations to be announced later this year.
• This investment raises Eli Lilly's total U.S. manufacturing commitments to $50 billion since 2020, supported in part by the 2017 corporate tax cuts.
• The announcement follows President Trump's push for reshoring manufacturing, including a proposed 25% tariff on pharmaceutical imports.
• The company aims to bolster domestic supply chains, reduce reliance on foreign suppliers, and meet growing demand for blockbuster drugs like Zepbound and Mounjaro.